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Translocation (9;22)(q34;q11.2) resulting in BCR/ABL1 fusion at the molecular level is the hallmark of chronic myelogenous
leukemia (CML). Variants of the Philadelphia translocation and complex translocations involving BCR have been reported
in myeloproliferative disorders (MPD). A rare translocation, t(9;22)(p24;q11.2), resulting in a novel BCR-JAK2 fusion has been
reported in a handful of cases of CML and acute myelogenous leukemia (AML). We present clinical-pathological and
cytogenetic evaluation of a patient with Philadelphia-chromosome negative CML/MPD harboring a t(9;22)(p24;q11.2)
resulting in BCR-JAK2 fusion. Fluorescence in situ hybridization and molecular characterization of the translocation
confirmed a BCR-JAK2 fusion and helped delineate the breakpoints upstream of exon 1 of minor cluster region of BCR
gene and likely intron 18 of the JAK2 gene, resulting in an in-frame transcript This case provides convincing support,
along with two previous case-reports, for a role for activation of the Janus kinase 2 in evolution of myeloproliferative
disease. The recurrent, albeit rare, nature of the breakpoints within BCR and JAK2 suggests a potential new diagnostic
target that should be interrogated in Ph-negative CML/MPD patients.
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The Philadelphia translocation is one of the most well
characterized cytogenetic aberrations seen in a vast major-
ity of cases of chronic myelogenous leukemia. The resulting
oncogenic BCR-ABL1 fusion transcript retains tyrosine
kinase activity and is the target of therapeutic tyrosine
kinase inhibitors. Janus kinases (JAKs) are a family of
receptor-associated tyrosine kinases that function through
interaction with specific cytokine receptors, principally via
signal transducers and activators of transcription (STATs)
[1]. Janus kinase 2 gene (JAK2), a specific mediator of
erythropoietin signaling, has been implicated in a whole
variety of myeloproliferative neoplasms [2-5]. A recurrent
dominant gain-of-function mutation in JAK2, JAK2V617F,
results in constitutional activation of its kinase domain and
has been widely established to be causally related to chronic
myeloproliferative disorders, particularly polycythemia vera.* Correspondence: Mohamed.M.Elnaggar@questdiagnostics.com
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reproduction in any medium, provided the orThe somatic V617F gain-of- function mutation in exon 14
of JAK2 gene, and less commonly exon 12 mutation of
JAK2 have found in greater than 95% of patients with
polycythemia vera and about 50% of patients with essential
thrombocythemia and myelofibrosis [6-8]. Additionally, a
single case report implicates a role for the V617F mutation
of JAK2 in de novo AML [9]. Interestingly, JAK2 has been
identified to be involved in two rare translocations: with
ETV6, at 12p13, in acute lymphoblastic leukemia and rarely
myeloproliferative (CML-like) disorder [4,10] and with
BCR, at 22q11.2, in patients with chronic myeloid leukemia
[11]. Here we report a case of chronic myeloid leukemia
(CML) with a translocation (9;22)(p24;q11.2), resulting in
BCR-JAK2 fusion, as a sole cytogenetic abnormality. The
fusion gene was confirmed at the molecular level. This case
report provides additional strong support for a role for
JAK2 activation in chronic myeloproliferative disorders.Clinical report
The patient is an 84 year-old male, who first presented
in October 2003 with complaints of fatigue, a 20 poundal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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night sweats, leukocytosis (98,6 k/uL with a predomin-
ance of neutrophils and less mature myelocytes and
metamyelocytes), anemia (Hb 10.9 g/dL), and normal
platelets count (283 k/uL). Physical exam was remark-
able for a protuberant abdomen with hepatosplenome-
galy and bilateral pitting edema at the mid calves.
Routine labs showed an elevated white blood cell count
of 36,600, low hemoglobin of 10.32 g/dL and normal
platelets of 275 k/uL. His differential showed 71.8%
neutrophils, 7.2% lymphocytes, 11.6% monocytes, 2.9%
eosinophils and 6.5% basophils. Bone marrow
aspiration and biopsy showed hypercellularity with
striking myeloid hyperplasia with complete granulocytic
maturation to segmented neutrophils (Figure 1). Only
rare erythroid precursors were present and their
maturation was normoblastic without nuclear: cytoplasmic
dyssynchrony. Megakaryocytes were adequate in number
without overt cytologic atypia and few hypolobated forms
present. There were no lymphoid infiltrates seen. Flow
cytometry showed hypogranular maturing myeloids with
no evidence of an increase in myeloid blasts. FluorescenceFigure 1 Bone marrow aspiration analysis showing striking myeloid h
neutrophils. Megakaryocytes were adequate in number without overt cyto
were no lymphoid infiltrates seen.in-situ hybridization (FISH) and real time RT-PCR were
both negative for BCR/ABL1 fusion gene (Figure 2).
Chromosome analysis showed a male chromosome
complement with an atypical translocation between the
short arm of chromosome 9 and the long arm of chromo-
some 22 [t(9;22)( p24;q11.2)] (Figure 3).
The patient was started on allopurinol 300 mg daily and
hydroxyurea 500 mg twice daily for presumed chronic
myelogenous leukemia in the chronic phase. After two
weeks of treatment, his white blood cell count decreased to
3,000 with an absolute neutrophil count of 2,320, his
hemoglobin decreased to 8 g/dL, and his platelets
decreased to 54 k/uL. His hydroxyurea was held for two
weeks and on a return visit, his WBC had climbed to 7,000
with an absolute neutrophil count of 5,090, hemoglobin
increased to 10.8 g/dL after 2 units of packed red blood
cells, and platelets increased to 168 k/uL. The patient was
lost to follow up until September 2005 when he was hospi-
talized for a bleeding gastrointestinal ulcer. His WBC count
increased to 22,000 without treatment, but the patient was
started on imatinib 400 mg twice daily at that time and was
then once again lost to follow up till the current visit.yperplasia with complete granulocytic maturation to segmented
logic atypia although a few hypolobated forms were present. There
A B
Figure 2 A BCR-ABL1 FISH for Ph chromosome revealed normal hybridization pattern [negative for t(9,22)(q34;q11.2) BCR/ABL1
fusion]. However, a third signal for 22q11.2 (BCR) probe was observed in 61 % of cells in interphase (panel A: green signal; arrows), suggestive of
an extra chromosome 22 or additional chromosome material containing the 22q11.2 region (panel B; red arrow).
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normocytic normochromic anemia (9.8 g/dL), normal
platelet count (332 k/uL), and high total leukocyte count
(32.4 k/uL) composed mainly of left-shifted granulocytes.
A repeat bone marrow aspiration and biopsy showed
hypercellularity and marked myeloid hyperplasia with a
mild left shift, mild dyserythropoiesis, and <5% blasts.
Megakaryocytes were again adequate in number and
morphology with no dysplastic changes. Cytogenetic exam-
ination of the patient’s bone marrow aspirate by conven-
tional G-banding analysis was performed on 2Figure 3 G-banded chromosome analysis (bone marrow) revealed an
apparently balanced translocation between the short arm of one chro
detected in 90 % of metaphases analyzed.unstimulated short-term cultures (24 and 48 hrs). Chromo-
some analysis showed the translocation (9;22)(p24;q11.2) as
a sole abnormality in 90% (18/20) of analyzed metaphases.
To exclude subtle BCR/ABL1 fusion due to three-way
translocation or insertion translocation, FISH assay was
performed using dual fusion probes (from Abbott Molecu-
lar-Vysis, Des Plaines, IL) for 9q34 (ABL1) and 22q11.2
(BCR) regions and excluded BCR-ABL1 fusion; however an
extra signal for the BCR probe was observed in 61% of
interphase nuclei. No mutations were seen in JAK2 exons
12–14 by Sanger sequencing.abnormal 46,XY, t(9;22)(p24;q11.2)[18]/46,XY [2] karyotype; an
mosome 9 and the long arm of one chromosome 22, which was
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RT-PCR and Sequencing of BCR-JAK2 Fusion Transcript
A potential BCR-JAK2 fusion was suspected based on the
chromosome analysis revealing a translocation t(9;22)( p24;
q11.2) and clinical diagnosis of MPD. Total RNA was
isolated from patient’s EDTA plasma sample by EasyMagW
extraction kit (BioMérieux, Durham, NC) following manu-
facturer’s instructions. A total of six individual RT-PCR
reactions were designed to determine the possible break-
points within BCR and JAK2 resulting in a fusion transcript.
The RT-PCR was performed using SuperScript™ III one
step RT-PCR systems with PlatinumW Taq DNA polymer-
ase (Invitrogen, Carlsbad, CA). The PCR conditions were
as follows: initial annealing step at 55°C for 30 min and 94°
C for 2 min, followed by 40 cycles of 94°C for 15 second,
60°C for 30 second and 68°C for 1 min and a final exten-
sion step of 68°C for 7 min. Specific PCR products, were
purified by MinElute gel extraction (MinElute™ Gel Ex-
traction Kit, Qiagen Cat. # 28606). The PCR products
were then sequenced in both forward and reverse direc-
tions using ABI PRISMW 3730XL genetic analyzer (Ap-
plied Biosystems, Foster City, CA). Sequencing data are
base-called by Sequencing Analysis software and NCBI
blast website (http://www.ncbi.nlm.nih.gov/blast/). RT-PCR
was performed using forward primers mapping to the cod-
ing sequences of exons 1 (5’-CCT CGC AGA ACT CGC
AAC A-3’), 13 (5’-GAG CTG CAG ATG CTG ACC AA-
3’), and 19 (5’-TGAAGGCAGCCTTCGACG-3’) of the
minor, major, and micro breakpoint regions of the BCRFigure 4 Direct sequencing of the RT-PCR product and sequence alig
highlighted in blue) and at nucleotide 2434 in JAK2 (nucleotides high
entire exon 1 of BCR fused to nt 1 of exon 19 of JAK2 in frame.locus, respectively [NC_000022.10]. We used 2 reverse pri-
mers mapping to exon 15 (5’- CCA TGC CAA CTG TTT
AGC AA-3’) and exon 20 of JAK2 gene (5’- TCA TAC
CGG CAC ATC TCC ACA C-3’) [NC_000009.11] [5,6].Results
A presumptive diagnosis of MPD and possible BCR-JAK2
fusion was suspected from chromosome and FISH analysis
revealing a translocation t(9;22)( p24;q11.2). Confirmation
and delineation of the fusion was pursued by additional
molecular analysis. A specific amplification product of
approximately 340 bp was obtained from the RT-PCR
reaction. Direct sequencing of the RT-PCR product and
sequence alignment revealed a fusion at nucleotide 1279 of
BCR and at nucleotide 2435 of JAK2 coding transcripts,
respectively; the fusion product included the entire exon 1
of BCR fused to nt 1 of exon 19 of JAK2, in frame (Figure 4).
There was no loss or insertion of a base at the breakpoints.
This would predict a break upstream of exon 1 at the BCR
genomic locus and within intron 18 of JAK2 locus. The
breakpoint within the BCR gene corresponds to the minor
breakpoint cluster region that results in the p190 BCR-ABL
fusion protein in CML [12,13]. The in-frame fusion product
is predicted to produce a 747 amino acid protein. The
predicted protein product likely includes the coiled–coil
oligomerization domain of BCR and the segment immedi-
ately distal to the JH2-pseudokinase domain of JAK2, thus
preserving its active protein tyrosine kinase domain.nment revealed a break at nucleotide 1279 in BCR (nucleotides
lighted in red and italicized); the fusion product included the
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Though relatively rare and likely under-diagnosed, the
BCR-JAK2 fusion event in this case with CML/MPD
adds to the spectrum of rare yet recurrent translocation
partners for each of the genes, respectively. The BCR
gene harbors two common breakpoints involved in the
formation of the two alternative forms of the Philadelphia
chromosome translocation seen in chronic myeloid
leukemia and acute lymphoblastic leukemia [14-16]. These
alternative breakpoints result in fusion of different exon
sets of BCR to a common subset of the exons of the ABL1
gene located on chromosome 9 [p210(BCR-ABL) and p190
(BCR-ABL)] with constitutive activation of ABL tyrosine
kinase.
JAK2 kinase is a member of a family of non-receptor
tyrosine kinases involved in non-catalytic cytokine receptor
signaling. The common gain-of-function mutation, V617F,
has been strongly associated with polycythemia vera,
essential thrombocythemia, and primary myelofibrosis.
Rare translocations involving JAK2 and resulting in fusion
transcripts with oncogenic potential have been described in
ALL and CML. Interestingly, the Drosophila Janus Kinase
homolog, hopscotch (hop) gene, influences proliferation
and differentiation of various cell types, particularly in
hematopoietic lineages; mutations in the Drosophila
hopscotch (hop) gene also cause proliferative defects [17].
These data provide evidence in support of a
leukemogenic role for BCR-JAK2 fusion in myeloprolifera-
tive disorders, including CML, and complements data pro-
vided by the first case report by Griesinger et al. [11]. To
our knowledge this represents the second case of CML-like
MPD with a translocation resulting in BCR-JAK2 fusion.
Interestingly, this case may also suggest the potential recur-
rent nature of the chromosomal breakpoints and resulting
in fusion between JAK2 and BCR genes. Breaks and fusions
between the serine/threonine kinase BCR gene and tyrosine
kinase JAK2 result in a fusion gene with a potential for con-
stitutive kinase activity [3]. This is accompanied by disrup-
tion of the normal functions of the individual counterparts.
Fusion of the oligomerization domain of BCR with the
crucial tyrosine kinase domain of JAK2 could be pre-
dicted to possess significant oncogenic potential. The
N-terminal oligomerization domain of BCR is essential
for the oncogenicity of the Bcr-Abl protein. Though
speculative, it may be reasonable to predict that an intact
tyrosine kinase domain of JAK2, under the influence of
the BCR oligomerization domain, would lead to phos-
phorylation and constitutive activity of JAK2 kinase activ-
ity and downstream oncogenic effects. Similar speculative
predictions have been proposed for oncogenic ETV6-
JAK2 fusion [4,10]. The impact of tyrosine kinase inhibitor
(TKI) therapy in cases with JAK2mutations and transloca-
tions is still unclear and likely ineffective in the few cases
reported with translocations. However, in this case,Imatinib therapy was initiated during the second encoun-
ter (two years post-diagnosis). Loss to follow-up for the
following five years precludes any conclusions regarding
the effect, or lack thereof, of Imatinib in this patient.
This report, complemented by data from previous
cases, strongly suggests shared pathways between JAK2
activation and oncogenic events resulting in ALL, CML
and probably additional lympho- and myeloproliferative
disorders. This makes it imperative to utilize multiple
diagnostic tools (chromosomes, FISH, etc.,) to ad-
equately investigate hematologic malignancies. Identifica-
tion of additional cases will provide the opportunity to
draw more explicit genotype-phenotype correlations and
implement beneficial therapeutic regimens.
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